Pharmacy substitution of Evista for a generic — for Brazil
In many countries, the pharmacist may dispense an authorised generic of Evista (Raloxifene) instead of the branded version, often automatically or unless the prescriber explicitly objects. The substitution is regulated, the active ingredient stays the same, and the practical implications at 60mg mostly come down to price, manufacturer and tablet appearance.
Brazil context
Substitution rules in Brazil are set by ANVISA (Agência Nacional de Vigilância Sanitária) and applied at dispensing. Brazilian farmácias and drogarias range from major chains (Drogasil, Pacheco, RaiaDrogasil) to small independents. Pharmacist counsel is common but less central than in Europe. For Evista, this typically means the pharmacist may swap to an authorised generic of Raloxifene unless the prescriber has marked the prescription "do not substitute"; the clinical effect at 60mg stays the same and the price difference in BRL usually goes to the patient's benefit.
- Regulator
- ANVISA (Agência Nacional de Vigilância Sanitária)
- Currency
- BRL
How substitution works
When the prescription specifies Evista, the pharmacist checks local rules: in some jurisdictions automatic substitution to the cheapest authorised generic is the default unless the doctor writes "do not substitute"; in others, the patient must explicitly accept or refuse the swap. The active ingredient Raloxifene stays the same, the strength stays the same (60mg), and the clinical effect is, on average, identical. Raloxifene binds estrogen receptors and produces tissue-selective effects: estrogen-agonist activity in bone (preserving bone mineral density) and on lipid metabolism (lowering LDL cholesterol), while…
What you can ask
According to local pharmacy practice, patients can usually ask for the brand even when the generic is offered, accepting the price difference. They can also ask the pharmacist about the specific generic being dispensed — manufacturer, country of production and excipients — particularly relevant for users with known sensitivities. The pharmacist is the right person to clarify the substitution rules in your jurisdiction.
Frequently asked questions
Why is the pharmacy giving me a different brand of Evista? ▾
The pharmacy is dispensing an authorised generic of Raloxifene that is bioequivalent to Evista. Local substitution rules and the price difference are the usual reasons. The active substance and clinical effect at 60mg are the same.
Can I refuse the generic and keep getting Evista? ▾
Usually yes — most jurisdictions let patients pay the price difference and continue with the brand. The pharmacist confirms whether refusing substitution is allowed locally and what the cost gap is.
Pharmacy substitution of Evista for a generic in other countries
- the United StatesFDA (Food and Drug Administration)
- the United KingdomMHRA (Medicines and Healthcare products Regulatory Agency)
- SpainAEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
- MexicoCOFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- ArgentinaANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
- GermanyBfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
- FranceANSM (Agence nationale de sécurité du médicament et des produits de santé)
- ItalyAIFA (Agenzia Italiana del Farmaco)
- CanadaHealth Canada
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.